ADMA Biologics Inc (ADMA) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Total Revenue Chart for ADMA Biologics Inc

ADMA Biologics Inc (ADMA) revenue for FY2025 was USD 510.2M, a 19.6% change from FY2024. ADMA Biologics Inc's revenue grew from USD 1.1M in 2012 to USD 510.2M in 2025 (45527.8% over 13 years). Earnings per share moved from USD -1.39 in 2012 to USD -0.33 in 2022. Revenue compound annual growth rate: 5-year CAGR of 64.6%, 10-year CAGR of 53.2%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$2.39B
Implied Share Price
$10.68
Enterprise Value
$2.24B
Revenue (TTM)
$512.28M
EBITDA
$224.19M
Profit Margin
32.98%
Trailing P/E
15.26
Forward P/E
9.78
Price/Book (MRQ)
5.32
Price/Sales (TTM)
4.67
EV/EBITDA
9.61
EV/Revenue
4.37
Dividend Yield
—
Book Value
$1.81
Free Cash Flow (FY2025)
$27.82M
Free Cash Flow Yield
1.16%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.